NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submissio ...

NEW YORK, June 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form ...

Group 1 - A class action has been filed on behalf of investors who purchased PepGen Inc. (NASDAQ:PEPG) securities between March 7, 2024, and March 3, 2025 [1] - PepGen is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, with its lead product candidate being PGN-EDO51 for Duchenne muscular dystrophy (DMD) [1] - Allegations against PepGen include misleading investors about the effectiveness and safety of PGN-EDO51, deficiencies in the CONNECT2 study, and overstated clinical and commercial prospects [2] Group 2 - On January 29, 2025, PepGen reported safety concerns in the CONNECT1 study and FDA concerns regarding the CONNECT2 study, leading to a stock price drop of $0.40 per share (21.74%) [3] - Following a press release on March 4, 2025, announcing a voluntary pause of the CONNECT2 study, PepGen's stock price fell by $0.53 per share (18.86%) [4] - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 8, 2025 [5]

Core Viewpoint - A class action lawsuit has been filed against PepGen Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its drug candidate PGN-EDO51 and its CONNECT2 study [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased PepGen's securities between March 7, 2024, and March 3, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against PepGen - The complaint alleges that PepGen's drug candidate PGN-EDO51 was less safe and effective than claimed [4]. - It is asserted that the CONNECT2 study was deficient for FDA approval and posed dangers to participants [4]. - The company is likely to halt its CONNECT2 study, leading to false and materially misleading public statements throughout the class period [4]. Group 3: Investor Communication - The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to contact them for assistance [5]. - Investors can reach out to the firm for a free discussion of their rights [3].

NEW YORK, June 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG) and certain officers.  The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-03221, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dat ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, PGN-EDO51, and its clinical study, CONNECT2 [1][2]. Allegations - The complaint claims that during the class period from March 7, 2024, to March 3, 2025, PepGen's statements regarding PGN-EDO51's effectiveness and safety were misleading [1]. - It is alleged that the CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [1]. - The lawsuit asserts that the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated, resulting in materially false public statements by the defendants [1]. Next Steps for Shareholders - Shareholders who purchased shares of PEPG during the specified timeframe are encouraged to register for the class action by August 8, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PepGen, Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). Investors have until ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased PepGen Inc. securities between March 7, 2024, and March 3, 2025, due to alleged misleading statements regarding the effectiveness and safety of PGN-EDO51 and the CONNECT2 study [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that PepGen made false and misleading statements about PGN-EDO51's effectiveness and safety, the CONNECT2 study's adequacy for FDA approval, and the overall clinical and commercial prospects of PGN-EDO51 [5]. - Investors who purchased PepGen securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors interested in joining the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 8, 2025, to represent the class in the lawsuit [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against PepGen Inc. and certain officers for alleged violations of federal securities laws during the Class Period from March 7, 2024, to March 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased PepGen securities during the specified Class Period [2]. - The complaint alleges that Defendants made materially false and misleading statements regarding the effectiveness and safety of PGN-EDO51, the CONNECT2 study's suitability for FDA approval, and the overall clinical and commercial prospects of PepGen [3]. Group 2: Next Steps for Investors - Investors who suffered losses in PepGen have until August 8, 2025, to request appointment as lead plaintiff in the class action [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful in the case [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered significant amounts for investors nationwide [6].

Core Viewpoint - A securities class action lawsuit has been filed against PepGen Inc. for allegedly making false and misleading statements regarding its lead product candidate, PGN-EDO51, and its clinical trials [1][2]. Group 1: Lawsuit Details - The lawsuit covers all investors who purchased PepGen securities between March 7, 2024, and March 3, 2025 [1]. - Investors are encouraged to contact the law firm before the lead plaintiff motion deadline of August 8, 2025 [2]. Group 2: Allegations Against PepGen - The complaint alleges that PepGen misrepresented the efficacy and safety of PGN-EDO51, claiming it was less effective than publicly stated [8]. - The CONNECT2 study was described as dangerous or deficient for obtaining FDA approval, undermining the drug's clinical, regulatory, and commercial prospects [8]. - The truth about the drug's performance began to emerge on July 30, 2024, when PepGen reported "positive clinical data" that fell short of expectations, leading to a significant stock price drop of 32.69% [3][4].